Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

We are fearless innovators on a mission to deliver functional improvement for individuals, families and communities. We pursue our goals with passion, determination, agility and urgency, recognizing that countless lives depend on our efforts. We are here to forever change lives. We know we will deliver.

1560 Trapelo Road
Waltham, MA 02451
  • Featured Employer

We’re looking for colleagues who share this ethos to join Dyne and help shape one of the most innovative and impactful biotech companies. If you’re driven to deliver for people living with neuromuscular diseases; if you put team and mission first; if you embrace bold ideas; if you are committed to accountability and transparency; if you have a drive to make a difference, we’d love to connect.

Discover our open positions

Hear from our Dynamos

We are on a mission to deliver functional improvement for individuals, families, and communities. The foundation of our efforts is driven by our exceptional team of Dynamos and their dedication to fostering an unparalleled culture. Hear Dynamos share their perspectives on their biotech careers and what makes Dyne a special place to work.

Collaborative Culture
On Now
Collaborative Culture
On Now
Commitment to Innovation
On Now
Passionate and Driven Team
NEWS
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets; BioSpace takes a look at how the FDA is functioning mid-shutdown.
The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar RNA-based pipeline in rare muscle diseases.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.
JOBS
IN THE PRESS